Bosutinib: A third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia

Keyphrases

• All-phase 16%
• Bosutinib 100%
• Chronic Myeloid Leukemia 100%
• Clinical Efficacy 16%
• Comorbid Conditions 16%
• Family Decision 16%
• Financial Factors 16%
• Inhibitory Activity 16%
• Intolerant 16%
• Oral Tyrosine Kinase Inhibitors 16%
• Patient Preference 16%
• Pharmacokinetics-pharmacodynamics (PK-PD) 16%
• Philadelphia Chromosome 16%
• Prescribing Patterns 16%
• Safety Self-efficacy 16%
• T315I 16%
• Third-generation Tyrosine Kinase Inhibitor 100%
• Tolerability 16%
• Toxicity Profile 16%
• Tyrosine Kinase Inhibitor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Bosutinib 100%
• Chronic Myeloid Leukemia 100%
• Epileptic Absence 16%
• Pharmacodynamics 16%
• Pharmacokinetics 16%
• Philadelphia 1 Chromosome 16%
• Protein Tyrosine Kinase Inhibitor 100%
• Tolerability 16%

Medicine and Dentistry

• Bosutinib 100%
• Chronic Myelogenous Leukemia 100%
• Epileptic Absence 16%
• Patient Preference 16%
• Pharmacodynamics 16%
• Pharmacokinetics 16%
• Philadelphia 1 Chromosome 16%
• Tyrosine-Kinase Inhibitor 100%